Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.
Also called NCT05460416
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 276 participants
- Sponsor
- Centre Hospitalier Universitaire de Liege
- Registry
-
NCT05460416 -
2024-516816-72-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium
- Registry status
- Recruiting
Technical summary
Registry record NCT05460416. Randomized; single masking; primary purpose prevention. Start 2022-10-25 (actual); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer
- Acronym
- TePPAFET
- Condition
- Embryo Transfer
- Condition
- Hypertension, Pregnancy Induced
- Intervention (Drug)
- Acetylsalicylic acid
- Lead sponsor
- Centre Hospitalier Universitaire de Liege
Record details
- Record id
cardio:ct-nct05460416- Content hash
d2c51e03dd5e219079fab3936e0b714dfd7536448615c599bfe5ca5291e62542